ReviewClinical, cosmetic and investigational dermatology2015
Oral submucous fibrosis: an update.
Review in Clinical, cosmetic and investigational dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Interventions for managing oral submucous fibrosis.The Cochrane database of systematic reviews · 2024Pooled it
- [Development of precancerous lesions of oral mucous membrane diseases and oral cancer animal models].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2020Pooled it
- Low-dose nicotine enhances arecoline-induced human oral mucosa fibroblast proliferation by stabilizing Egr-1 protein.Odontology · 2026Article
- A systematic review of staging systems for oral submucous fibrosis: evolution, variations, and clinical implications.Frontiers in oral health · 2026Review
- An organoid-guided roadmap for precision delivery of epigallocatechin gallate in oral submucous fibrosis.Frontiers in bioengineering and biotechnology · 2026Review
- Delineating novel diagnostic biomarkers and therapeutic targets for oral submucosal fibrosis: an integrative multi-omics and machine learning approach.Frontiers in bioinformatics · 2026Article
- Betel nut chewing and its implications for airway management: a single-centre survey of knowledge and experience.British journal of anaesthesia · 2025Article
- Lip, Oral Cavity, and Pharyngeal Cancers: Global Epidemiology, Risk Factors, and Prevention: A Narrative Review.Health science reports · 2025Article
- Lichen planus-the role of age and gender in clinical appearance and treatment : A narrative review.Wiener medizinische Wochenschrift (1946) · 2025Review
- Role of optical imaging in oral cancer and oral potentially malignant disorders: implications for oral submucous fibrosis.Frontiers in oral health · 2025Review
- Determining Disease Activity and Glucocorticoid Response in Thyroid-Associated Ophthalmopathy: Preliminary Study Using Dynamic Contrast-Enhanced MRI.Korean journal of radiology · 2024Article
- Computational analysis of phytocompounds inHeliyon · 2024Article
- To Estimate and Compare the Level of Serum Immunoglobulin A in Patients of Oral Submucous Fibrosis, Leukoplakia, and Control Group.Journal of pharmacy & bioallied sciences · 2024Article
- Prevalence and risk factors of oral potentially malignant disorders in Indonesia: a cross-sectional study undertaken in 5 provinces.Scientific reports · 2024Article
- Polyphenol-based targeted therapy for oral submucous fibrosis.Inflammopharmacology · 2023Article
- Evaluation of Digital Palmar Dermatoglyphics in Oral Submucous Fibrosis and Leukoplakia: A Prospective Comparative Clinical Study.Journal of maxillofacial and oral surgery · 2022Article
- Pulmonary function test: A critical domain in oral submucous fibrosis patients.Journal of education and health promotion · 2022Article
- Arecoline Is Associated With Inhibition of Cuproptosis and Proliferation of Cancer-Associated Fibroblasts in Oral Squamous Cell Carcinoma: A Potential Mechanism for Tumor Metastasis.Frontiers in oncology · 2022Article
- Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer.Frontiers in pharmacology · 2022Review
- Expression of Ki67 Biomarker in Oral Submucous Fibrosis with Clinico-Pathological Correlations: A Prospective Study.Asian Pacific journal of cancer prevention : APJCP · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSF) is a premalignant condition caused by betel chewing. It is very common in Southeast Asia but has started to spread to Europe and North America. OSF can lead to squamous cell carcinoma, a risk that is further increased by concomitant tobacco consumption. OSF is a diagnosis based on clinical symptoms and confirmation by histopathology. Hypovascularity leading to blanching of the oral mucosa, staining of teeth and gingiva, and trismus are major symptoms. Major constituents of betel quid are arecoline from betel nuts and copper, which are responsible for fibroblast dysfunction and fibrosis. A variety of extracellular and intracellular signaling pathways might be involved. Treatment of OSF is difficult, as not many large, randomized controlled trials have been conducted. The principal actions of drug therapy include antifibrotic, anti-inflammatory, and antioxygen radical mechanisms. Potential new drugs are on the horizon. Surgery may be necessary in advanced cases of trismus. Prevention is most important, as no healing can be achieved with available treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.